Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 4NETWORK 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 16Lymphoid 8Breast 6Sarcoma 4Genitourinary 4CNS 3Plasma cell 2Other neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Multiple Myeloma 2Precancerous Conditions 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Dexamethasone 48Bortezomib 22Lenalidomide 20Cyclophosphamide 20daratumumab 18Calcium Dobesilate 15Melphalan 13Thalidomide 12carfilzomib 9pomalidomide 7Prednisone 7dexamethasone acetate 6dexamethasone 21-phosphate 6auricularum 6Peripheral Blood Stem Cell Transplantation 6Doxorubicin 6isatuximab 5Filgrastim 5Vincristine 4Interferon-alpha 3Etoposide 3selinexor 2sargramostim 2ixazomib 2elotuzumab 2cobimetinib 2belantamab mafodotin 2Steroids 2Stem Cell Transplantation 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Microarray Analysis × Plasma cell × Clear all
NCT00900263 2016-10-07

S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

SWOG Cancer Research Network

Completed
375 enrolled
Other neoplasmPlasma cell

Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions

NCT01055301 2015-03-06

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

SWOG Cancer Research Network

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡